NHS Framework Agreement for South of England Branded - Tranche B and Annual
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 12 Aug 2022
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
United Kingdom: Please refer to Document No. 10 for a full list of participating authorities
1 buyer
- NHS England Leeds
29 suppliers
- Mylan Potters Bar
- Bayer Reading
- Biogen Maidenhead
- Merck Sharpe & Dohme London
- Ul Global Pharma Watford
- Celltrion Healthcare Slough
- CST Pharma Walsall
- Ipsen Slough
- Pfizer Kent
- Teva Castleford
- Merck Serono Feltham
- Takeda London
- Eli Lilly Basingstoke
- Aventis Pharma Reading
- Sandoz Surrey
- Roche Products Welwyn Garden City
- Janssen Cilag Highwycombe
- Novo Nordisk Gatwick
- Typharm Norwich
- Almirall Uxbridge
- Sobi Swedish Orphan Biovitrum Great Abington
- Astrazeneca London
- Thornton & Ross Linthwaite
- Glaxosmithkline London
- Zentiva Pharma London
- Accord Barnstaple
- Ucb Pharma Slough
- Organon Pharmaceuticals London
- Gedeon Richter London
Description
CM/PHR/20/5611/01 - NHS Framework for SOUTH of England Branded Medicines - Tranche BCM/PHR/20/5611/02 - NHS Framework for the SOUTH of England Branded Medicines - Annual Tranche
Lot Division
| 1 | CM/PHR/20/5611/01 - NHS Framework for SOUTH of England Branded Medicines NHS South of England Branded Medicines - Tranche B Offer reference number: CM/PHR/20/5611 CM/PHR/20/5611/01 … - Tranche B. Period of framework: 1 September 2022 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5611/02 … - Annual Tranche. Period of framework: 1 September 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Further to II.2.5 - Price is not the only award criterion and all criteria are stated only in the procurement documents |
| 2 | CM/PHR/20/5611/02 - NHS Framework for the SOUTH of England Branded Medicines NHS South of England Branded Medicines - Tranche BOffer reference number: CM/PHR/20/5611CM/PHR/20/5611/01 … - Tranche B. Period of framework: 1 September 2022 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5611/02 … - Annual Tranche. Period of framework: 1 September 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Further to II.2.5 - Price is not the only award criterion and all criteria are stated only in the procurement documents |
Award Detail
| 1 | Mylan (Potters Bar)
|
| 2 | Bayer (Reading)
|
| 3 | Biogen (Maidenhead)
|
| 4 | Merck Sharpe & Dohme (London)
|
| 5 | Ul Global Pharma (Watford)
|
| 6 | Celltrion Healthcare (Slough)
|
| 7 | CST Pharma (Walsall)
|
| 8 | Ipsen (Slough)
|
| 9 | Pfizer (Kent)
|
| 10 | Teva (Castleford)
|
| 11 | Merck Serono (Feltham)
|
| 12 | Takeda (London)
|
| 13 | Eli Lilly (Basingstoke)
|
| 14 | Aventis Pharma (Reading)
|
| 15 | Sandoz (Surrey)
|
| 16 | Roche Products (Welwyn Garden City)
|
| 17 | Janssen Cilag (Highwycombe)
|
| 18 | Novo Nordisk (Gatwick)
|
| 19 | Typharm (Norwich)
|
| 20 | Almirall (Uxbridge)
|
| 21 | Merck Sharpe & Dohme (London)
|
| 22 | Celltrion Healthcare (Slough)
|
| 23 | Sobi Swedish Orphan Biovitrum (Great Abington)
|
| 24 | Astrazeneca (London)
|
| 25 | Thornton & Ross (Linthwaite)
|
| 26 | Pfizer (Kent)
|
| 27 | Glaxosmithkline (London)
|
| 28 | Teva (Castleford)
|
| 29 | Zentiva Pharma (London)
|
| 30 | Accord (Barnstaple)
|
| 31 | Takeda (London)
|
| 32 | Eli Lilly (Basingstoke)
|
| 33 | Aventis Pharma (Reading)
|
| 34 | Roche Products (Welwyn Garden City)
|
| 35 | Janssen Cilag (Highwycombe)
|
| 36 | Ucb Pharma (Slough)
|
| 37 | Organon Pharmaceuticals (London)
|
| 38 | Gedeon Richter (London)
|
Award Criteria
| price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-031f24
- FTS 022264-2022